Shares of Affimed (NASDAQ:AFMD) plunged 23% in early trading Tuesday after the company reported updated data from a clinical trial of AFM24 in combination with atezolizumab in the treatment of non ...

The study reported a 71% disease control rate and significant clinical activity, highlighting potential efficacy of AFM24 with atezolizumab. Affimed shares are trading higher Monday after the ...

In 33 heavily pretreated NSCLC EGFR wild-type (EGFRwt) patients the combination of AFM24 and atezolizumab shows an overall response rate (ORR) of 21% (6 confirmed responses, 1 response awaiting ...

the combination trial of its AFM24 innate cell engager ICE® with atezolizumab in non-small cell lung cancer. The conference call will be available via phone and webcast. The live audio webcast of ...

Patients with advanced hepatocellular carcinoma (HCC) receiving atezolizumab-bevacizumab treatment were more likely to experience variceal bleeding if they had a low platelet count, main portal ...

Relevance section written by JCO Associate Editor Gary K. Schwartz, MD, FASCO. The phase Ib COSMIC-021 study evaluated cabozantinib plus atezolizumab in patients with advanced solid tumors. Presented ...